Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
8.34
+0.02 (0.24%)
Nov 6, 2026, 4:00 PM EST - Market closed
Atrium Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Atrium Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $22. The average 1-year stock price forecast is 163.79% higher than the current stock price, while the lowest is $15 (+79.86%) and the highest is $25 (+199.76%).
Price Target: $22 (+163.79%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Atrium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 3 | 3 | 4 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 3 | 3 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 → $20 | Buy | Reiterates | $25 → $20 | +139.81% | Oct 28, 2026 |
| Roth MKM | Roth MKM | Buy Initiates $15 | Buy | Initiates | $15 | +79.86% | Oct 22, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 | Buy | Maintains | $25 | +199.76% | Oct 15, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $25 | Buy | Maintains | $25 | +199.76% | Oct 2, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $25 | Buy | Initiates | $25 | +199.76% | May 15, 2026 |
Financial Forecast
Revenue This Year
35.02M
from 18.62M
Increased by 88.07%
Revenue Next Year
1.60M
from 35.02M
Decreased by -95.43%
EPS This Year
-3.87
EPS Next Year
-5.96
from -3.87
EPS and Forward PE are based on non-GAAP adjusted numbers.